Clinical Trials in Connecticut

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Status

Study

Lead sponsor

Phase

Enrol

US states

Start

Recruiting

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

NCT07397338Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC

Revolution Medicines, Inc.

Phase 1/2

370

California, Connecticut, Minnesota, Tennessee, Texas, Virginia

2026-01-30

Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)

Revolution Medicines, Inc.

Phase 3

590

Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas

2025-05-06

Recruiting

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

NCT06917079Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Phase 1

665

California, Connecticut, Florida, Illinois, Massachusetts, New York, Tennessee, Texas

2025-03-31

Recruiting

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

NCT06657222Advanced Solid Tumors, HNSCC, SCLC, NSCLC

Tubulis GmbH

Phase 1/2

250

Connecticut, Florida, Massachusetts, Minnesota, Missouri, New York, Ohio, Texas

2024-12-13

Recruiting

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

NCT06343402Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Phase 1

350

Alabama, California, Colorado, Connecticut, Illinois, Kansas, Maryland, Michigan

2024-05-22

Recruiting

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

NCT05753722Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer, NSCLC

Incendia Therapeutics

Phase 1

270

Arizona, Connecticut, Massachusetts, Oregon, Pennsylvania, Tennessee, Texas, Virginia

2023-03-03

Active, closed

Study of Oral MRT-2359 in Selected Cancer Patients

NCT05546268NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL

Monte Rosa Therapeutics, Inc

Phase 1/2

174

Arizona, California, Connecticut, Kansas, Massachusetts, Michigan, Missouri, New York

2022-10-12

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 18 September 2026. https://priyalifescience.com/clinical-trials-usa/state/connecticut

Query this register directly

GET /api/trials?country=usa&status=recruiting&format=json Try it now →